Abstract 828P
Background
Translocation t(11;14) is one of the most common primary translocations in multiple myeloma (MM). In the era of the novel anti-myeloma agents, the exact prognostic role of t(11;14) remains to be determined.
Methods
We analyzed prospectively collected data from 1011 consecutive patients with newly diagnosed MM (NDMM) in a single institution (1997-2023). Approval was obtained by the institutional ethics committee. All patients were tested for t(11;14), +1q21, t(4;14), t(14;16), del(17p), del(13q) at diagnosis using standard FISH in CD138+ selected cells. Positivity was defined as at least 20% of clonal cells harboring t(11;14).
Results
89 out of 1011 patients (8.8%) had the t(11;14). The median age was 68 years and 54% were males. Patients with t(11;14) did not have a statistically significant difference in progression-free survival (PFS) compared with those who did not had t(11;14) [hazard ratio (HR) 1.25, p=0.15]. Interestingly, patients with isolated positivity for t(11;14) did not have a statistically significant difference in PFS compared with those without any abnormalities (HR 1.28, p=0.282). However, patients with t(11;14) and at least another cytogenetic abnormality had inferior PFS (HR 1.38, p=0.001). More specifically, those with t(11;14) and del17p (HR 3.74, 95%CI: 1.53-9.17, p=0.004) and those with t(11;14) and 1q21 amplification/addition (HR 1.67, 95%CI: 1.00-2.78, p=0.05) had dismal outcomes. Similarly, there was no statistically significant difference in overall survival (OS) between patients with and without t(11;14) (HR 1.31, 95%CI: 0.86-2.00, p=0.21). Patients who had at least an additional cytogenetic abnormality had inferior OS (HR 1.68, p<0.001). Patients with isolated t(11;14) did not demonstrate inferior OS compared with those without any abnormalities (HR 0.61, p=0.33). The co-presence of del17p (HR 6.03, p<0.001) or 1q21 amplification/addition (HR 2.51, p=0.006) with t(11;14) had a detrimental impact on OS.
Conclusions
Isolated t(11;14) in patients with NDMM does not seem to be a marker of adverse prognosis, whereas the co-presence of other high-risk cytogenetic abnormalities confers dismal outcomes. For those patients, BCL-2 targeted therapies have to be validated in future studies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
224P - Lung cancer scRNA-seq analyses reveal potential mechanisms causing different efficacy of target therapy and immunotherapy between EGFR 19del and L858R lung adenocarcinoma
Presenter: Hao Wang
Session: Poster session 09
225P - Nivolumab for cancer of unknown primary (CUP): Clinical efficacy and biomarker analysis from NivoCUP2 expanded access program (WJOG14620M)
Presenter: Junko Tanizaki
Session: Poster session 09
226TiP - CLEAR-Me: Interception trial to detect and clear molecular residual disease in patients with high-risk melanoma
Presenter: Erick Saldanha
Session: Poster session 09
227TiP - A phase II, open label, randomized, non-comparative cohorts study of adjuvant atezolizumab or atezolizumab plus tiragolumab in solid tumors with resectable disease with intermediate-high risk of recurrence and high tumor mutational burden (TMB-H) or microsatellite instability (MSI-H)
Presenter: Guillermo Antonio De Velasco Oria
Session: Poster session 09
228TiP - FINPROVE: The Finnish national study to facilitate patient access to targeted anti-cancer drugs
Presenter: Mika Mustonen
Session: Poster session 09
229TiP - A phase II trial of a neural network-based treatment decision support tool in patients (pts) with refractory solid organ malignancies
Presenter: Robert Walsh
Session: Poster session 09
230TiP - Exploring mechanisms of action and resistance in innovate cancer therapies: The UNLOCK program
Presenter: Beatriz Alonso de Castro
Session: Poster session 09
694P - Sequential high-dose-chemotherapy with 4 cycles paclitaxel, ifosfamide, carboplatin, etoposide (P-ICE) in relapsed/refractory male germ cell cancer: Final results with 15.8 years follow-up
Presenter: Hans Joachim Schmoll
Session: Poster session 09
695P - Assessment of the utility of CT scans in the long-term follow-up of metastatic non-seminomatous germ cell tumours (mNSGCT): The Late CT study
Presenter: Deep Chakrabarti
Session: Poster session 09
696P - Post chemotherapy retroperitoneal lymph node dissection (PC-RPLND) for metastatic pure seminoma
Presenter: David Pfister
Session: Poster session 09